ライフサイエンスコーパス: therapeutic hypothermia

1 agent administration in patients undergoing therapeutic hypothermia.

2 ere compared with patients who received mild therapeutic hypothermia.

3 ognosticate in postarrest patients receiving therapeutic hypothermia.

4 t hospital arrival and decreases the time to therapeutic hypothermia.

5 temperature seen during this period of mild therapeutic hypothermia.

6 in cardiogenic shock might benefit from mild therapeutic hypothermia.

7 ion in cardiac arrest survivors who received therapeutic hypothermia.

8 s in comatose, postarrest patients receiving therapeutic hypothermia.

9 Post-cardiac-arrest therapeutic hypothermia.

10 mains an accurate predictor of outcome after therapeutic hypothermia.

11 dations for cooling, and ongoing research on therapeutic hypothermia.

12 t neurological impairment is not affected by therapeutic hypothermia.

13 nts may be used to manage overt shivering in therapeutic hypothermia.

14 nse is effective, thus impeding induction of therapeutic hypothermia.

15 Exposure: Induction of therapeutic hypothermia.

16 euromuscular blockade in patients undergoing therapeutic hypothermia.

17 e queried regarding use of postresuscitation therapeutic hypothermia.

18 non-United States respondents had never used therapeutic hypothermia.

19 cardiopulmonary resuscitation and the use of therapeutic hypothermia.

20 r cardiac arrest, who were treated with mild therapeutic hypothermia.

21 matose cardiac arrest survivors treated with therapeutic hypothermia.

22 after out-of-hospital cardiac arrest receive therapeutic hypothermia.

23 ent to beyond 72 hours in cases treated with therapeutic hypothermia.

24 ed eighteen patients (77%) were treated with therapeutic hypothermia.

25 that infections are a common complication of therapeutic hypothermia.

26 nitor degree of block in patients undergoing therapeutic hypothermia.

27 -term outcomes in patients treated with mild therapeutic hypothermia.

28 versial data are available on the effects of therapeutic hypothermia.

29 The primary outcome was the initiation of therapeutic hypothermia.

30 ypothermia (33 degrees C for 16 hrs) or mild therapeutic hypothermia 1 xenon (70% for 1 hr).

31 survived the observation period in the mild therapeutic hypothermia 1 xenon group while one animal i

32 Mild therapeutic hypothermia 1 xenon preserved cardiac output

33 Clinically, only the mild therapeutic hypothermia 1 xenon-treated animals showed s

34 ital cardiac arrest (6.0%) were treated with therapeutic hypothermia; 1524 of these patients (mean [S

35 m "targeted temperature management" replace "therapeutic hypothermia." 2) The jury opines that descri

36 Likewise, therapeutic hypothermia (30 degrees C) inhibited Drp1-S6

37 ypothermia, to simulate temperatures used in therapeutic hypothermia (32 degrees C), were subjected t

38 The planned duration of therapeutic hypothermia (32 degrees C-34 degrees C) in b

39 Studies showing the effectiveness of therapeutic hypothermia (32-34 degrees C) in postcardiac

40 pigs were randomized to receive either mild therapeutic hypothermia (33 degrees C for 16 hrs) or mil

41 iglets were randomized to the following: (i) therapeutic hypothermia (33.5 degrees C from 2 to 26 h a

42 ients aged more than 75 frequently underwent therapeutic hypothermia (97.7%), urgent coronary angiogr

43 s, heart transplant, external defibrillation/therapeutic hypothermia, advances in surgical myectomy,

44 The protective mechanisms of therapeutic hypothermia affect the ischaemic cascade acr

45 Therapeutic hypothermia after cardiac arrest improves su

46 igorous exchange transfusion may enable mild therapeutic hypothermia after cardiac arrest in patients

47 Therapeutic hypothermia after cardiac arrest is feasible

48 sought to evaluate current physician use of therapeutic hypothermia after cardiac arrest, to ascerta

49 activation occurs during rewarming from mild therapeutic hypothermia after cardiac arrest.

50 considered a contraindication to the use of therapeutic hypothermia after cardiac arrest.

51 Seventy-five patients with CA treated with therapeutic hypothermia after cardiac resuscitation were

52 ight patients with cardiac arrest treated by therapeutic hypothermia after cardiac resuscitation were

53 In patients treated with therapeutic hypothermia after out-of-hospital cardiac ar

54 were for planning an interventional trial of therapeutic hypothermia after pediatric cardiac arrest.

55 lled trial evaluating the effect of (48 hrs) therapeutic hypothermia after severe traumatic brain inj

56 ital discharge in patients treated with mild therapeutic hypothermia after sudden cardiac arrest.

57 tive effects of combining inhaled xenon with therapeutic hypothermia after transient cerebral hypoxia

58 otective effects of combining melatonin with therapeutic hypothermia after transient hypoxia-ischaemi

59 sure, elevated intra-abdominal pressure, and therapeutic hypothermia after ventricular fibrillation-a

60 f the metabolic phase of cardiac arrest with therapeutic hypothermia, agents to treat or prevent repe

61 Despite treatment with therapeutic hypothermia, almost 50% of infants with neon

62 pothermia significantly better than did mild therapeutic hypothermia alone (4.6 6 0.6 L/min vs. 3.2 6

63 This study tested whether therapeutic hypothermia altered levels of inflammatory m

64 mmatory molecules, and it is unknown whether therapeutic hypothermia alters this inflammatory respons

65 Eighty-eight percent of patients underwent therapeutic hypothermia and 471 (18%) exhibited myoclonu

66 est on a large cohort of patients undergoing therapeutic hypothermia and at investigating its added v

67 scitated but comatose patients that includes therapeutic hypothermia and early catheterization/interv

68 Therapeutic hypothermia and extracorporeal membrane oxyg

69 efore, we tested the hypothesis whether mild therapeutic hypothermia and hyperoxia would attenuate po

70 pecific miRNAs were found to be sensitive to therapeutic hypothermia and may therefore be important t

71 sible association between bradycardia during therapeutic hypothermia and neurologic outcome in comato

72 spontaneous circulation who did not receive therapeutic hypothermia and never exceeded 37.5 degrees

73 acute inflammatory events are attenuated by therapeutic hypothermia and other anti-inflammatory stra

74 aggressive postresuscitation care, including therapeutic hypothermia and percutaneous coronary interv

75 Therapeutic hypothermia and pharmacological sedation may

76 Except for therapeutic hypothermia and revascularization, no novel

77 1ra did not significantly change during mild therapeutic hypothermia and rewarming, although low valu

78 time in cardiac arrest patients during mild therapeutic hypothermia and rewarming.

79 jective: To evaluate the association between therapeutic hypothermia and survival after in-hospital c

80 ns, strongly suggests an association between therapeutic hypothermia and the risk of pneumonia and se

81 However, only the combination of mild therapeutic hypothermia and xenon resulted in reduced as

82 Ninety-seven percent received therapeutic hypothermia, and overall survival was 46%.

83 This is the first case of therapeutic hypothermia applied to postarrest care of a

84 Additional treatments for therapeutic hypothermia are required to maximize neuropr

85 vival and neurological outcomes benefit from therapeutic hypothermia are robust when compared over a

86 tation care of cardiac arrest patients using therapeutic hypothermia as part of nontrial treatment.

87 available clinical evidence does not support therapeutic hypothermia as standard therapy for acute my

88 ren who survived in-hospital cardiac arrest, therapeutic hypothermia, as compared with therapeutic no

89 who survived out-of-hospital cardiac arrest, therapeutic hypothermia, as compared with therapeutic no

90 Formal guidelines recommend that therapeutic hypothermia be considered after in-hospital

91 e associated with an increased likelihood of therapeutic hypothermia being initiated.

92 Therapeutic hypothermia blunts the expression of these m

93 Bradycardia is frequent during therapeutic hypothermia, but its impact on outcome remai

94 urvivors of cardiac arrest subjected to mild therapeutic hypothermia, but the underlying mechanisms a

95 ental and clinical data that examine whether therapeutic hypothermia can improve functional outcomes

96 Therapeutic hypothermia can improve survival after cardi

97 sing over the years, clinical application of therapeutic hypothermia cannot be recommended for routin

98 Conclusive efficacy trials assessing therapeutic hypothermia combined with reperfusion therap

99 ents with in-hospital cardiac arrest, use of therapeutic hypothermia compared with usual care was ass

100 To buy time, the induction of therapeutic hypothermia (core temperature 32 degrees C-3

101 and treatment by cardiac arrest centers for therapeutic hypothermia, coronary artery evaluation and

102 These findings suggest that mild therapeutic hypothermia could be a therapeutic option in

103 We hypothesize that systemic therapeutic hypothermia could decrease morbidity and mor

104 Therapeutic hypothermia decreases brain tissue injury in

105 rmia are arrhythmogenic, patients undergoing therapeutic hypothermia do not have an increase in arrhy

106 Therapeutic hypothermia during cardiac arrest and after

107 cal reports have suggested that induction of therapeutic hypothermia during cardiopulmonary resuscita

108 tal of 1198 patients were assigned to either therapeutic hypothermia during CPR (618 patients) or sta

109 One technique for induction of mild therapeutic hypothermia during CPR is a rapid infusion o

110 Overall 10.2% of patients allocated to therapeutic hypothermia during CPR were alive at hospita

111 of outcome-modifying interventions, such as therapeutic hypothermia following cardiac arrest.

112 ular-blocking agents for patients undergoing therapeutic hypothermia following cardiac arrest.

113 rent studies have demonstrated that applying therapeutic hypothermia for 12 to 24 hours after resusci

114 Treatment with mild therapeutic hypothermia for 24 hours followed by passive

115 ts from previous trials, we assessed whether therapeutic hypothermia for 48-72 h with slow rewarming

116 ular fibrillation who were treated with mild therapeutic hypothermia for 72 hrs.

117 Treatment with mild therapeutic hypothermia for 72 hrs.

118 We aimed to determine the use of therapeutic hypothermia for adult in-hospital cardiac ar

119 Although therapeutic hypothermia for cardiac arrest survivors has

120 domized clinical trial to assess efficacy of therapeutic hypothermia for in-hospital cardiac arrest.

121 Therapeutic hypothermia for post-MI cardiogenic shock ha

122 urs was significantly less in the Xenon+mild therapeutic hypothermia group (p=0.04).

123 e in outcomes 12 months after injury; in the therapeutic hypothermia group, four (17%) had a bad outc

124 rapeutic hypothermia group, n=17; Xenon+mild therapeutic hypothermia group, n=16).

125 Thirty-three patients were evaluable (mild therapeutic hypothermia group, n=17; Xenon+mild therapeu

126 ith target temperature of 33 degrees C (mild therapeutic hypothermia group, n=18) alone or in combina

127 et concentration of at least 40% (Xenon+mild therapeutic hypothermia group, n=18) for 24 hours.

128 utic hypothermia group=5.30 mg vs Xenon+mild therapeutic hypothermia group=2.95 mg, p=0.06).

129 ia was lower in xenon-treated patients (mild therapeutic hypothermia group=5.30 mg vs Xenon+mild ther

130 Therapeutic hypothermia has been shown in randomized cli

131 Therapeutic hypothermia has been shown to decrease neuro

132 Therapeutic hypothermia has been used to attenuate the e

133 Therapeutic hypothermia has demonstrated considerable be

134 Because positive hemodynamic effects of mild therapeutic hypothermia have been suggested, we aimed at

135 Therapeutic hypothermia (HT) is standard care for modera

136 sedative requirements early in the course of therapeutic hypothermia improve the identification of pa

137 Whether therapeutic hypothermia improves important outcomes afte

138 Post-cardiac-arrest therapeutic hypothermia improves outcomes in comatose ca

139 Hemodynamic effects of mild therapeutic hypothermia in 20 consecutive patients admit

140 t study supporting a role of cooling caps in therapeutic hypothermia in adults.

141 Early therapeutic hypothermia in children with severe traumati

142 entation of "poor prognosis" occurred during therapeutic hypothermia in more than half of patients in

143 ety of inhaled xenon treatment combined with therapeutic hypothermia in out-of-hospital cardiac arres

144 man data provides a rationale for the use of therapeutic hypothermia in patients with acute liver fai

145 option for early and effective induction of therapeutic hypothermia in settings of cardiopulmonary r

146 e neuroprotective effect of (prolonged) mild therapeutic hypothermia in the delayed hypoperfusion pha

147 Therapeutic hypothermia in the ICU requires mechanical v

148 apoE4 allele, with GCS score, sex, race, and therapeutic hypothermias included as covariates.

149 The use of therapeutic hypothermia increased from 0.7% in 2003 to 3

150 omized controlled trials, in that the use of therapeutic hypothermia increased survival with an odds

151 However, therapeutic hypothermia increases sepsis risk and uninte

152 Mild therapeutic hypothermia induced a significant decrease i

153 y investigated whether a shorter duration of therapeutic hypothermia induced quickly and early after

154 Therapeutic hypothermia initiated 0, 1, 4, and 8 hrs aft

155 Therapeutic hypothermia initiated with cardiopulmonary r

156 Despite the introduction of mild therapeutic hypothermia into postcardiac arrest care, ce

157 Therapeutic hypothermia is a highly promising treatment,

158 Early introduction of mild therapeutic hypothermia is an established treatment goal

159 Therapeutic hypothermia is associated with significantly

160 Therapeutic hypothermia is being clinically used to redu

161 Therapeutic hypothermia is commonly used to improve neur

162 sis that the efficacy of post-cardiac-arrest therapeutic hypothermia is dependent on the onset and du

163 Therapeutic hypothermia is likely a beneficial treatment

164 Although therapeutic hypothermia is now established to improve re

165 Therapeutic hypothermia is recommended by international

166 Therapeutic hypothermia is recommended for comatose adul

167 Although therapeutic hypothermia is relatively easy to implement,

168 Importance: Therapeutic hypothermia is used for patients following b

169 Therapeutic hypothermia is widely employed for neuroprot

170 gnesium, phosphodiesterase 3 inhibitors, and therapeutic hypothermia, is emerging.

171 cardiac index remained unchanged under mild therapeutic hypothermia likely due to an increase in eje

172 The time to therapeutic hypothermia (<34 degrees C) was 3.2 hrs in t

173 Sedation with volatile anesthetics during therapeutic hypothermia may be a feasible short-acting o

174 These data suggest that therapeutic hypothermia may decrease arrhythmogenesis du

175 Mild therapeutic hypothermia may improve survival and neurolo

176 Mild therapeutic hypothermia (MTH) has been integrated into i

177 s with ischemic heart disease, the effect of therapeutic hypothermia on arrhythmia susceptibility dur

178 The effects of therapeutic hypothermia on drug disposition include both

179 ctive cohort study, we examine the impact of therapeutic hypothermia on ER in survivors of cardiac ar

180 To ascertain more precisely the effect of therapeutic hypothermia on neonatal cerebral injury, we

181 Our objective was to determine the effect of therapeutic hypothermia on oxidative damage after severe

182 of this study was to evaluate the impact of therapeutic hypothermia on phenytoin levels and pharmaco

183 This review examines the effects of therapeutic hypothermia on the disposition, metabolism,

184 Despite the association of ER with ID-VF, therapeutic hypothermia only increases ER amplitude in C

185 Increasingly, the use of therapeutic hypothermia or ketogenic diet is described a

186 l cardiopulmonary resuscitation with/without therapeutic hypothermia, or sham groups.

187 For improved adoption of therapeutic hypothermia, our data suggest that developme

188 who had cardiac arrest and were treated with therapeutic hypothermia over a 7-year period were consid

189 ed accurate predictors of poor outcome after therapeutic hypothermia (p < 0.0001 for all).

190 e initial rhythms from the Penn Alliance for Therapeutic Hypothermia (PATH) registry between 2000 and

191 t rate was significantly lower in Xenon+mild therapeutic hypothermia patients during hypothermia (p=0

192 We measured the proportion of therapeutic hypothermia patients who achieved target tem

193 2-34 degrees C) was not achieved in 44.3% of therapeutic hypothermia patients within 24 hours and 17.

194 Patients admitted in the therapeutic hypothermia period had a mean esophageal tem

195 rvival to hospital discharge improved in the therapeutic hypothermia period in patients with an initi

196 ventricular fibrillation patients during the therapeutic hypothermia period trended toward improved s

197 The therapeutic hypothermia period was associated with a sig

198 During the therapeutic hypothermia period, 204 patients were brough

199 to 26 h after resuscitation, n = 8) and (ii) therapeutic hypothermia plus intravenous melatonin (5 mg

200 than 20 mm Hg after traumatic brain injury, therapeutic hypothermia plus standard care to reduce int

201 An active cooling therapeutic hypothermia protocol, using ice packs, cooli

202 crease or did not have documented use of the therapeutic hypothermia protocol.

203 the process of developing and implementing a therapeutic hypothermia protocol.

204 gic outcome at discharge associated with the therapeutic hypothermia protocol.

205 We conclude that in cardiogenic shock mild therapeutic hypothermia provides circulatory support and

206 c-ischemic encephalopathy who have undergone therapeutic hypothermia, quantitative magnetic resonance

207 Patients allocated to therapeutic hypothermia received a mean (SD) of 1193 (64

208 Accordingly, patients with mild therapeutic hypothermia required lower cumulative doses

209 In this study, post-cardiac-arrest therapeutic hypothermia resulted in comparable improveme

210 t exposure to xenon during induction of mild therapeutic hypothermia results in significant improveme

211 cardiac output during the induction of mild therapeutic hypothermia significantly better than did mi

212 Therapeutic hypothermia significantly reduces phenytoin

213 s), electroencephalography reactivity during therapeutic hypothermia, somatosensory-evoked potentials

214 both free and total levels demonstrated that therapeutic hypothermia specifically decreased the time-

215 spontaneous circulation with an endovascular therapeutic hypothermia system placed in the right atriu

216 an 18 years of age were randomly assigned to therapeutic hypothermia (target temperature, 33.0 degree

217 an 18 years of age were randomly assigned to therapeutic hypothermia (target temperature, 33.0 degree

218 Therapeutic hypothermia (TH) attenuates reperfusion inju

219 Therapeutic hypothermia (TH) improves survival and confe

220 percutaneous coronary intervention (PCI) and therapeutic hypothermia (TH) on long-term prognosis.

221 After the beginning of mild therapeutic hypothermia, the patient experienced maligna

222 In all patients, we induced therapeutic hypothermia to 33 degrees C during the first

223 The intervention group had therapeutic hypothermia to a temperature of 32-33 degree

224 Twenty-one therapeutic hypothermia-treated patients after out-of-ho

225 In therapeutic hypothermia-treated patients after out-of-ho

226 ere randomly assigned to receive either mild therapeutic hypothermia treatment with target temperatur

227 e sedation with the AnaConDa during 24 hours therapeutic hypothermia, until rewarming.

228 The rate of therapeutic hypothermia use after in-hospital cardiac ar

229 Factors associated with therapeutic hypothermia use included patient age, time a

230 patients with persisting coma after CPR and therapeutic hypothermia, use of motor score or NSE, as r

231 f-hospital cardiac arrest, induction of mild therapeutic hypothermia using a rapid infusion of large-

232 Therapeutic hypothermia was also associated with lower r

233 Therapeutic hypothermia was associated with a reduction

234 Bradycardia during therapeutic hypothermia was associated with good neurolo

235 After adjustment, therapeutic hypothermia was associated with lower in-hos

236 rformed, spontaneous perfusion restored, and therapeutic hypothermia was attempted for neural protect

237 CONCLUSIONS/SIGNIFICANCE: Therapeutic hypothermia was implemented appropriately wi

238 d 65% +/- 16%* of normal, respectively, when therapeutic hypothermia was initiated 0, 1, 4, or 8 hrs

239 Of 67,498 patients, therapeutic hypothermia was initiated in 1,367 patients

240 These outcomes were not different when therapeutic hypothermia was maintained for 24 vs. 48 hrs

241 e, surviving neuron counts were greater when therapeutic hypothermia was maintained for 48 hrs compar

242 utic window and greater neuroprotection when therapeutic hypothermia was maintained for 48 vs. 24 hrs

243 OR, 1.9 [1.4-2.6]), whereas no difference in therapeutic hypothermia was noted.

244 red the content of hemoglobin S to 5.6%, and therapeutic hypothermia was successfully maintained for

245 After in-hospital cardiac arrest, therapeutic hypothermia was used rarely.

246 ected of suffering asphyxial encephalopathy--therapeutic hypothermia- was implemented in the UK.

247 rrest rigorous exchange transfusion and mild therapeutic hypothermia were applied.

248 were kept normothermic, those who underwent therapeutic hypothermia were associated with 18% reducti

249 Patients undergoing therapeutic hypothermia were excluded.

250 tal of 55 consecutive patients who underwent therapeutic hypothermia were reviewed between September

251 thermia (<37.5 degrees C) compared with mild therapeutic hypothermia were studied.

252 cal and clinical studies have suggested that therapeutic hypothermia, while decreasing neurologic inj

253 postanoxic encephalopathy treated with mild therapeutic hypothermia within 24 hours after cardiac ar